ML-179 (CID 45100448) is a small-molecule selective antagonist of the Frizzled 8 (FZD8) receptor, inhibiting the Wnt/β-catenin signaling pathway. It is primarily utilized in research settings, particularly in the field of medicinal chemistry and drug discovery. As a potent and selective inhibitor, it is valuable for studying biological pathways related to Wnt signaling and disease mechanisms, such as cancer, inflammation, and metabolic disorders. Researchers employ ML-179 in in vitro and in vivo studies to understand cellular processes, evaluate its efficacy as a lead compound for new drug development, and explore interactions with specific molecular targets in biochemical assays. This aids in optimizing drug candidates targeting Wnt pathway dysregulation.